This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CANTA BTA Stock Overview

A biotechnology company, develops antibody-based treatments for life threatening diseases. More details

CANTA BTA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 50.11% per year

Risk Analysis

Shares are highly illiquid

Earnings are forecast to decline by an average of 3.4% per year for the next 3 years

Makes less than USD$1m in revenue (SEK0)

Does not have a meaningful market cap (SEK343M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Cantargia AB (publ) Competitors

Alzinova

OM:ALZ

SEK 283.5m

Oncopeptides

OM:ONCO

SEK 293.1m

Medivir

OM:MVIR

SEK 327.5m

Ascelia Pharma

OM:ACE

SEK 303.2m

Price History & Performance

Summary of share price highs, lows and changes for Cantargia
Historical stock prices
Current Share Price	SEK 1.79
52 Week High	SEK 2.00
52 Week Low	SEK 1.60
Beta	1.72
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	8.48%

Recent updates

Shareholder Returns

	CANTA BTA	SE Biotechs	SE Market
7D	7.2%	2.5%	4.4%
1Y	n/a	11.7%	13.1%

Return vs Industry: Insufficient data to determine how CANTA BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how CANTA BTA performed against the Swedish Market.

Price Volatility

Is CANTA BTA's price volatile compared to industry and market?
CANTA BTA volatility
CANTA BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	5.8%
10% most volatile stocks in SE Market	11.9%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: CANTA BTA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: Insufficient data to determine CANTA BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	21	Goran Forsberg	cantargia.com

Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.

Cantargia AB (publ) Fundamentals Summary

How do Cantargia's earnings and revenue compare to its market cap?
CANTA BTA fundamental statistics
Market cap	SEK 343.13m
Earnings (TTM)	-SEK 193.53m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-1.8x

P/E Ratio

Is CANTA BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CANTA BTA income statement (TTM)
Revenue	SEK 0
Cost of Revenue	SEK 0
Gross Profit	SEK 0
Other Expenses	SEK 193.53m
Earnings	-SEK 193.53m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 21, 2025

Earnings per share (EPS)	-1.05
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did CANTA BTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/17 19:48
End of Day Share Price	2025/01/15 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cantargia AB (publ) is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Arvid Necander	Carnegie Investment Bank AB
Soo Romanoff	Edison Investment Research
null null	Life Sciences Research International BV